胰性脑病临床治疗的探讨

目的：探讨胰性脑病（PE）临床治疗方法,降低重症急性胰腺炎（SAP）的病死率。方法：SAP伴发的早期可疑PE7例,采用重组人生长激素（ rhGH）治疗,4U／次,每日2次,5－7天。联合用药组以生长抑素合用rhGH治疗SAP,共13例,剂量及时间同早期PE组。结果：应用后rhGH24h,病人精神障碍改善,48－72h后症状消失,本组7例全部治愈。联合用药治疗SAP13例,未见PE的发生。结论：生长激素对早期PE有治疗作用,生长激素与生长抑素联合应用有可能降低PE的发生。     

日本血吸虫重组抗原的免疫原性鉴定

为发展新的日本血吸虫病疫苗候选抗原分子，对已构建的阳性表达克隆PGsj24进行大量诱导表达，制备为20kD的重组抗原。以之免疫家兔，产生了较强的抗体反应。该单特导抗血清可识别成上天然蛋白中与重组蛋白相对应的抗原成分。两者分子量及Westernblot识别反应带型均基本一致，说明约20kD重组蛋白确为日本血吸虫基因编码产物，具有较强的免疫原性，可刺激机体产生较强的免疫应答。     

A simple and rapid approach to develop recombinant avian herpesvirus vectored vaccines using CRISPR/Cas9 system

Herpesvirus of turkeys (HVT) has been successfully used as live vaccine against Marek's disease (MD) worldwide for more than 40 years either alone or in combination with other serotypes. HVT is also widely used as a vector platform for generation of recombinant vaccines against a number of avian diseases such as infectious bursal disease (IBD), Newcastle disease (ND) and avian influenza (AI) using conventional recombination methods or recombineering tools on cloned viral genomes. In the present study, we describe the application of CRISPR/Cas9-based genome editing as a rapid and efficient method of generating HVT recombinants expressing VP2 protein of IBDV. This approach offers an efficient method to introduce other viral antigens into the HVT genome for rapid development of recombinant vaccines.     

A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein

Proteinase 3 (PR3)-specific antineutrophil cytoplasmic autoantibodies (PR3-ANCA) recognize conformational epitopes on PR3. This study evaluates PR3-ANCA target epitopes utilizing a novel recombinant PR3 (rPR3) produced to accommodate manipulations of the N-terminal domain. The rPR3 molecule contains an N-terminus six histidine tag, which can be removed by enterokinase (EK) cleavage of an adjacent EK cleavage site. Once cleaved the remaining amino acids correspond to the mature N-terminus of PR3. This rPR3 can be manipulated to produce three variant forms: tagged rPR3^+his, EK-cleaved (his-tag removed) rPR3^{? his}, and EK-cleaved, denatured/refolded rPR3^{? his/dr} (the proteolytically active form). Patients with clinically positive PR3-ANCA titers (n = 40) were confirmed for reactivity against purchased native PR3 in our system. Controls included 29 healthy volunteers and 34 MPO-ANCA patients. All PR3-ANCA sera samples tested were reactive with one or more forms of the recombinant protein (greater than mean ELISA OD 405 + 2 SDs of controls). Of significance, three sera were reactive with non-active forms only and three others were more reactive with rPR3^{? his/dr} than with native PR3. The results of our evaluation of PR3-ANCA sera for reactivity against the three forms of our rPR3 protein uniquely exemplify the diverse array of epitopes within the PR3-ANCA population. This new recombinant form of PR3 should provide a suitable approach to mapping ANCA epitopes using site-directed mutagenesis.     

Antigenic characterisation of yeast-expressed lyssavirus nucleoproteins

In Europe, three genotypes of the genus Lyssavirus, family Rhabdoviridae, are present, classical rabies virus (RABV, genotype 1), European bat lyssavirus type 1 (EBLV-1, genotype 5) and European bat lyssavirus type 2 (EBLV-2, genotype 6). The entire authentic nucleoprotein (N protein) encoding sequences of RABV (challenge virus standard, CVS, strain), EBLV-1 and EBLV-2 were expressed in yeast Saccharomyces cerevisiae at high level. Purification of recombinant N proteins by caesium chloride gradient centrifugation resulted in yields between 14-17, 25-29 and 18-20 mg/l of induced yeast culture for RABV-CVS, EBLV-1 and EBLV-2, respectively. The purified N proteins were evaluated by negative staining electron microscopy, which revealed the formation of nucleocapsid-like structures. The antigenic conformation of the N proteins was investigated for their reactivity with monoclonal antibodies (mAbs) directed against different lyssaviruses. The reactivity pattern of each mAb was virtually identical between immunofluorescence assay with virus-infected cells, and ELISA and dot blot assay using the corresponding recombinant N proteins. These observations lead us to conclude that yeast-expressed lyssavirus N proteins share antigenic properties with naturally expressed virus protein. These recombinant proteins have the potential for use as components of serological assays for lyssaviruses.     

寻常型天疱疮自身抗原Dsg3片段的重组表达和特异性细胞反应

目的 :探讨寻常型天疱疮自身抗原Dsg3在特异性T细胞反应中的作用 ,为自身免疫性疾病机制的研究提供依据。方法 :根据Genbank中的Dsg3序列分析 ,采用RT PCR法克隆自身抗原Dsg3E1,E2 ,E3,E4,E5多肽片段的cDNA ,定向插入表达载体PGEX 2T ,导入大肠杆菌JM10 9中表达重组融合蛋白并经GST层析柱纯化 ;进一步与PV患者及疾病对照组、正常对照组T细胞混合培养 ,观察T细胞增殖反应。结果 :Dsg3E1,E2和E4,E5可刺激PV患者T细胞反应 ,而不与疾病对照组、正常对照组反应。结论 :Dsg3E1,E2和E4,E5中包含T B细胞作用相关的抗原表位 ,在PV发病中起重要作用。     

幽门螺杆菌GroEL蛋白重组表达及表达产物小鼠免疫保护作用

目的 检测幽门螺杆菌临床菌株groEL基因序列差异,确定重组表达的GroEL蛋白(r-GroEL)抗原性、免疫反应性以及对幽门螺杆菌感染小鼠的免疫保护性.方法 采用PCR及测序法了解幽门螺杆菌临床菌株groEL基因序列.构建幽门螺杆菌groEL基因pET42a-E.coli BL21DE3原核表达系统,采用SDS-PAGE及凝胶图像分析系统确定rGroEL表达量,Ni-NTA亲和层析法提纯rGroEL.采用ELISA和Western blot检测rGroEL的抗原性和免疫反应性,采用幽门螺杆菌全菌为包被抗原的ELISA确定GroEL膜定位.采用幽门螺杆菌小鼠感染模型了解rGroEL免疫保护作用.结果 35株幽门螺杆菌临床菌株groEL基因序列相似性高达99.4％～ 100％.rGroEL表达量可达细菌总蛋白的56％,SDS-PAGE后提纯的rGroEL在凝胶中显示为单一的条带.rGroEL可诱导家兔和小鼠产生高效价IgG抗体,同时也能被幽门螺杆菌全菌抗体(Hp-IgG)或rGroEL-IgG识别并与之结合.GroEL是幽门螺杆菌表面蛋白抗原.50、100或200 μg rGroEL免疫可分别使50.0％ (6/12)、75.0％ (9/12)和91.7％ (11/12)小鼠免于幽门 螺杆菌SS1株的感染,200 μg rGroEL免疫保护率(91.7％)显著高于50μg rGroEL(50.0％)( P＜0.05).结论 幽门螺杆菌GroEL蛋白是序列保守、具有良好免疫原性和免疫保护性的表面抗原,可作为基因工程疫苗候选抗原.     

乳腺癌特异性转导小肽融合表达载体的构建以及目的蛋白的表达

目的构建乳腺癌特异性转导小肽PI-增强型绿色荧光蛋白融合蛋白的原核表达载体,并进行目的蛋白的表达、分离和纯化。方法合成PI的DNA序列,将其定向插入到p EGFPN2中,经双酶切获取PI-EGFP的核苷酸序列,再将其克隆入原核表达质粒pET-28a(+),构建出pET-28a(+)-PI-EGFP的原核表达载体;重组质粒转化BL21(DE3)pLysS感受态细胞,经IPTG诱导表达,利用His-tag对蛋白进行分离纯化,SDS-PAGE电泳和蛋白质印迹免疫分析(Western blot)鉴定纯化蛋白质。结果成功构建了pET-28a(+)-PI-EGFP的原核表达载体;其经诱导后,在大肠杆菌中高效表达,目的蛋白以可溶性形式存在;SDS-PAGE分析显示,在相对分子量约33kD的位置出现目的蛋白条带,与理论值相符;经His TALONTM Cartridge亲和层析纯化获得了高纯度的重组的PI-EGFP融合蛋白,Western blot鉴定结果显示获得了目的蛋白。结论成功构建出乳腺癌特异性转导小肽PI-增强型绿色荧光蛋白融合蛋白原核表达载体,并能够表达出PI-EGFP的融合蛋白,为进一步研究小肽的乳腺癌特异性转导功能奠定基础。